Search

Displaying results 9811 - 9820 of 10000 in total
  1. Drug

    Ansornitinib

    go.drugbank.com/drugs/DB21577
    Experimental

    The usage of the INN stem '-tinib' in the name indicates that Ansornitinib is a tyrosine kinase inhibitor. Ansornitinib has a monoisotopic molecular weight of 540.25 Da.

  2. Drug

    Garsorasib

    go.drugbank.com/drugs/DB21581
    Investigational

    The usage of the INN stem '-rasib' in the name indicates that Garsorasib is a Ras protein inhibitor. Garsorasib has a monoisotopic molecular weight of 598.26 Da.

  3. Drug

    Gumelutamide

    go.drugbank.com/drugs/DB21615
    Experimental

    The usage of the INN stem '-lutamide' in the name indicates that Gumelutamide is a non-steroid antiandrogen. Gumelutamide has a monoisotopic molecular weight of 420.15 Da.

  4. Drug

    Frevecitinib

    go.drugbank.com/drugs/DB21681
    Investigational

    The usage of the INN stem '-citinib' in the name indicates that Frevecitinib is a Janus kinase inhibitor. Frevecitinib has a monoisotopic molecular weight of 415.18 Da.

  5. Drug

    Odentegravir

    go.drugbank.com/drugs/DB21708
    Experimental

    The usage of the INN stem '-tegravir' in the name indicates that Odentegravir is a HIV integrase inhibitor. Odentegravir has a monoisotopic molecular weight of 421.12 Da.

  6. Drug

    Pafuramidine

    go.drugbank.com/drugs/DB06532
    Investigational

    Pafuramidine, a prodrug of furamidine, currently has orphan status for Pneumocystis jiroveci pneumonia.

  7. Drug

    Epothilone D

    go.drugbank.com/drugs/DB01873
    Investigational

  8. Drug

    RPI-78M

    go.drugbank.com/drugs/DB05740
    Experimental

    RPI-78M is being developed for the treatment of multiple sclerosis (MS). Other neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and amyotrophic lateral sclerosis (ALS).

  9. Drug

    AT-7519

    go.drugbank.com/drugs/DB08142
    Investigational

    AT7519 is a selective inhibitor of certain Cyclin Dependent Kinases (CDKs) leading to tumour regression. It is developed by Astex for the treatment of solid tumours and haematological malignancies.

    Synonyms: 4-{[(2,6-dichlorophenyl)carbonyl]amino}-N-piperidin-4-yl-1H-pyrazole-3-carboxamide
  10. Drug

    NF-kappaB Decoy

    go.drugbank.com/drugs/DB05559
    Investigational